Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

87 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Lymphoma NCT00290498

- 27.09.21 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290498

Eligibility NCT01200758 Non-Hodgkin's Lymphoma - Eligibility

- 27.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01200758

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

- 20.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866047

Eligibility Lymphoma NCT02056548

- 20.09.21 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 20.09.21 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Eligibility Lymphoma NCT00517699

- 20.09.21 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00517699

Eligibility NCT01190449 Lymphoma - CALGB 50901 Eligibility Checklist Form 3211939_v1_0 - CALGB 50901 Eligibility Checklist Form

- 20.09.21 - 1 Formular, 1 Itemgruppe, 29 Datenelemente, 2 Sprachen
Itemgruppe: Eligibility Checklist
CALGB 50901 Eligibility Checklist Form Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F9012C3-FDE5-DB91-E040-BB89AD432434

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Patient Enrollment/ Patient Eligibility - Demographics; General Medical History; Prior Therapy; History of Lymphoma

- 18.03.21 - 1 Formular, 13 Itemgruppen, 46 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Demographics (Enrollment), Investigator Signature, For Coulter Use Only, Demographics (General Medical History), Medical History Date, General Medical History, Prior Therapy, Prior Radiation Therapy, History of Lymphoma, Lymphoma Cell Type, Lymphoma Grade , History of Lymphoma
Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Eligibility Lymphoma NCT01831505

- 18.07.20 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents; ODM derived from: https://clinicaltrials.gov/show/NCT01831505

Eligibility Lymphoma NCT01590732

- 18.07.20 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01590732

Eligibility Lymphoma NCT01410630

- 18.07.20 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01410630

Eligibility Lymphoma NCT01751412

- 17.07.20 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Proton Radiation for Lymphoma Involving Mediastinum; ODM derived from: https://clinicaltrials.gov/show/NCT01751412

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video